Management Call: Suven Pharma Acquisition by Advent International
Conference Call with Suven Pharma Management and Analysts on the acquisition of the Jasti family stake by Advent International. Listen to the transcript.27-12-2022
27-12-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our conference call intimation dated December 26, 2022, that audio recording of the conference call for the investors held on Monday, December 26, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/news-events27-12-2022
Advent International buys Suven Pharma for Rs 6,313 crore
Advent will also launch an open offer for an additional 26% of the company, a listed contract research and manufacturing services (CRAMS) business, at the same Rs 495 per share from minority shareholders. If fully subscribed to, Advent could end up paying 9,589 crore, making it its largest takeover in India yet.27-12-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on today i.e. Monday, December 26, 2022 at 2:30 PM IST to discuss today's announcement that Advent International is to acquire a significant stake in Suven Pharmaceuticals from the Jasti Family. This is for your information and record.26-12-2022
Suven Pharmaceuticals Ltd - 543064 - Open Offer
Kotak Mahindra Capital Company Ltd ("Manager to the Open Offer") has submitted to BSE a copy of Public Announcement for the attention of the public shareholders of Suven Pharmaceuticals Ltd ("Target Company") under Regulation 3(1) and Regulation 4 read with Regulations 13, 14 and 15(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and subsequent amendments thereto.26-12-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to inform you that the Board of Directors of the Company have been informed by our Promoter, Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust), that they have executed a Share Purchase Agreement with Berhyanda Limited, a Cyprus based company on December 26, 2022. Attached please find Press Release of the acquirer. This intimation is also being uploaded on the Company's website at www.suvenpharm.com This is for your information and record.26-12-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed the copy of the newspaper advertisement regarding to Public Notice for issue of 'Letter of Confirmation' in lieu of duplicate share certificates as per the SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022. The advertisement as appeared today i.e. December 23, 2022 in Financial Express.23-12-2022
Suven Pharmaceuticals Ltd - 543064 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions for the half-year ended 30th September, 2022. This is for your information and record.21-11-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the earnings conference call for the quarter and half-year ended September 30, 2022 conducted after the meeting of Board of Directors held on November 8, 2022. The above information has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.15-11-2022
Suven Pharmaceuticals Ltd - 543064 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and with reference to our Results conference call intimation dated November 3, 2022, that audio recording of the conference call for the quarter and half-year ended September 30, 2022 held on Wednesday, November 9, 2022, has been uploaded on the Company''s website at https://www.suvenpharm.com/index.php/investors/financial-info/quarterly-release This is for your information and record.10-11-2022